Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

See more here:
OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Scroll to Top